This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Epilepsy	Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB)	<p>Mouse studies suggest NTRK2 inhibitors could help treat temporal lobe epilepsy. Upregulation of NTRK2 signaling is associated with status epilepticus and subsequent temporal lobe epilepsy in patients. In a mouse model for epilepsy, an Ntrk2 inhibitor decreased the frequency and number of seizures, anxiety-like behaviors and damage to hippocampal neurons compared with vehicle. In the treated mice, reductions in frequency and number of seizures persisted for five to six weeks after discontinuation of the inhibitor, whereas vehicle-treated controls showed an increase in seizure frequency and number over the same period. Future studies could include identifying and testing inhibitors of human NTRK2.</p> <p>SciBX 6(28); doi:10.1038/scibx.2013.730 Published online July 25, 2013</p>	Patent status undisclosed; unlicensed; available for partnering	<p>Liu, G. <i>et al. Neuron</i>; published online June 20, 2013; doi:10.1016/j.neuron.2013.04.027 Contact: James O. McNamara, Duke University Medical Center, Durham, N.C. e-mail: jmc@neuro.duke.edu</p>